Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial

• Published in: Hepatology international Vol. 15; no. 6; pp. 1431 - 1441
• Main Authors: Shi, Ming, Li, Yuan-Yuan, Xu, Ruo-Nan, Meng, Fan-Ping, Yu, Shuang-Jie, Fu, Jun-Liang, Hu, Jin-Hua, Li, Jing-Xin, Wang, Li-Feng, Jin, Lei, Wang, Fu-Sheng
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01.12.2021; Springer Nature B.V
• Subjects: Bilirubin; Cell therapy; Cholinesterase; Cirrhosis; Colorectal Surgery; Complications; Follow-Up Studies; Health services; Hepatocellular carcinoma; Hepatocytes; Hepatology; Humans; Liver; Liver cancer; Liver cirrhosis; Liver Cirrhosis - therapy; Medicine; Medicine & Public Health; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Original; Original Article; Patients; Prospective Studies; Prothrombin; Serum albumin; Side effects; Stem cells; Surgery; Survival; Treatment Outcome; Umbilical cord; Long-term survival; Liver function; Adverse events; HBV infection; Decompensated liver cirrhosis; Clinical trial; Prospective open-labeled study; Umbilical cord; Randomized controlled study; Mesenchymal stem cells
• ISSN: 1936-0533; 1936-0541; 1936-0541
• DOI: 10.1007/s12072-021-10199-2

Background Mesenchymal stem cell (MSC) infusion was reported to improve liver function in patients with decompensated liver cirrhosis (DLC); however, whether the medication can improve outcome of these patients is poorly understood. Methods This prospective, open-labeled, randomized controlled study enrolled 219 patients with HBV-related DLC who were divided into control group ( n  = 111) and umbilical cord-derived MSC (UC-MSC)-treated group ( n  = 108), then all of them received a follow-up check from October 2010 to October 2017. The treated patients received three times of UC-MSC infusions at 4-week intervals plus conventional treatment that was only used for control group. The overall survival rate and HCC-free survival rate were calculated as primary endpoints and the liver function and adverse events associated with the medication were also evaluated. Results During the follow-up check period from 13 to 75th months, there was a significantly higher overall survival rate in the treated group than the control group, while the difference of the hepatocellular carcinoma event-free survival rate between the treated and control groups was not observed during the 75-month follow-up. UC-MSC treatment markedly improved liver function, as indicated by the levels of serum albumin, prothrombin activity, cholinesterase, and total bilirubin during 48 weeks of follow-up. No significant side effects or treatment-related complications were observed in the UC-MSC group. Conclusions Therapy of UC-MSC is not only well tolerated, but also significantly improves long-term survival rate, as well as the liver function in patients with HBV-related DLC. UC-MSC medication, therefore, might present a novel therapeutic approach for the disease. Graphic abstract